Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03430011
What this trial is testing

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene 165
Early research (Phase 1)Active Not RecruitingNCT03399799
What this trial is testing

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 279
Not applicableLooking for participantsNCT01137643
What this trial is testing

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
UNC Lineberger Comprehensive Cancer Center 15,000
Early research (Phase 1)UnknownNCT05266768
What this trial is testing

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Chunrui Li 36
Not applicableEnded earlyNCT01077440
What this trial is testing

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

Who this might be right for
Cancer SurvivorChronic Myeloproliferative DisordersLeukemia+6 more
Vanderbilt University 24
Large-scale testing (Phase 3)Study completedNCT02755597
What this trial is testing

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 291
Early research (Phase 1)Study completedNCT00509691
What this trial is testing

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Who this might be right for
Cancer
University of Louisville 20
Testing effectiveness (Phase 2)Study completedNCT01745640
What this trial is testing

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Who this might be right for
Multiple Myeloma
University Hospital, Lille 63
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Early research (Phase 1)Looking for participantsNCT07558915
What this trial is testing

Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Genentech, Inc. 160
Early research (Phase 1)UnknownNCT05920876
What this trial is testing

QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT00903968
What this trial is testing

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 58
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT04176718
What this trial is testing

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaMultiple Myeloma in Relapse+1 more
Andrew Yee, MD 44
Post-approval studies (Phase 4)Study completedNCT03416374
What this trial is testing

Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 45
Early research (Phase 1)Study completedNCT00036790
What this trial is testing

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersColorectal Cancer+9 more
University of Wisconsin, Madison
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07421856
What this trial is testing

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma Refractory
Hebei Senlang Biotechnology Inc., Ltd. 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04835129
What this trial is testing

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Medical College of Wisconsin 28
Early research (Phase 1)Active Not RecruitingNCT05308654
What this trial is testing

Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 34
Early research (Phase 1)Study completedNCT01568294
What this trial is testing

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 12
Next Page